A Randomized Trial of Ubiquinone Replacement in Women with Heart Failure

proposal by Liviu Klein, MD, MS
Liviu.Klein@ucsf.edu

Brief Study Description

- **Participants: 1200** based on adjudicated UNC HF events
  - Balanced: baseline age groups, ethnicities, duration of HF
  - Randomized in a double blind fashion after a 30 day run in phase to ubiquinone 100 mg or placebo TID
- **All participants:**
  - Receive an Android smartphone and will perform monthly self-guided 6MWT and KCCQ functional assessments
  - BNP obtained at baseline, 12 months and end of the study using a novel, home based, point of care home testing
  - 25% of participants: modified bathrooms scales that will track weekly their body weight and myocardial function using BCG
- **Clinical events (HF hospitalizations; CV mortality):**

Novel Methods of Outcomes Ascertainment



6MWT and KCCQ App

Home point of care BNP

Novel Methods of Outcomes Ascertainment



BCG



Decompensated (ΔR-J = -15 ms)	Compensated (ΔR-J = -80 ms)
Rest (110ms)	Rest (225ms)
Post 6MWT (95ms)	Post 6MWT (145ms)

50 ms